Biological
Flublok Quadrivalent
Flublok Quadrivalent is a biological therapy with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
1
25%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_4
Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years
NCT05514002
completed
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
NCT03694392
terminatedphase_2
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
NCT03658629
completedphase_3
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
NCT02290509
Clinical Trials (4)
Showing 4 of 4 trials
NCT05514002Phase 4
Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years
NCT03694392
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
NCT03658629Phase 2
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
NCT02290509Phase 3
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4